Protalix BioTherapeutics Inc (NYSEAMERICAN: PLX) is making a run for the top in the premarket hours this morning, and for good reason. The company announced that the FDA has accepted a Biologics License Application, or BLA. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
PLX Stock Is Climbing
In the press release, Protalix BioTherapeutics announced that it, and its commercialization partner, Chiesi Global Rare Disease, received acceptance of a Biologics License Application from the FDA. Moreover, the FDA has granted Priority Review designation for the drug.
Read more at Alpha Stock News!